Omocor-Lovaza launch by Joe Z and Paul Huff in 2005
Omacor(original name-changed to Lovaza in July 2007 at FDA request) was launched by Joe Zakrzewski and Paul Huff. They achieved:
2005 sales close to 150mil.$
2006 sales 300 mil.$
2007 Sales 500 mil.$ -- GSK press release said 341 mil.$ in 9 months of 2007--an increase of 62% over the same period in 2006.
Now tell me -DO YOU CONSIDER this a GOOD LAUNCH or Bad launch?
What's my point: Amarin senior management is capable of launching VASCEPA by themselves.
GSK did not do any wonders by moving sales from 500mil.$ in 2007 to 900mil.$ in 2011.
Look at VERTEX--vs.Merck for Hep.C drug.
Although Merck got approval 3 weeks earlier from FDA, Vertex hit the road so fast that it achieved over 700 mil.$ sales in 5 months and 1.6 bil.$ next year.
TRUST me-- MERCK,GSK are bureaucratic co.--slow to make decisions.
If they launched VASCEPA--Sales growth will be slower.
Based on Actual facts, Small co.are fast on feet with less bosses to review every decision.Large co.have too many bosses to MICROMANAGE.
Vertex beat Merck--even after starting 4 weeks delay in FDA approval-gaining 75% Market share in 5 months.
Same thing happened with Omacor/Lovaza--Sales grew 100% to reach 341 mil.$ in 9months of 2007. GSK Press release says that the growth was 62% over same period of 2006.
By the time GSK took over in 2008(as purchase happened on Nov.21,2007), Lovaza sales were 500 mil.$.
GSK grew it from 500 to 900 mil.$ in 4 years to 900 mil.$.
Pronova--owner of patents was able to grow sales to 500mil.$ in other countries. Total sales in 2011--GSK(Lovaza) + Omacor in Europe =900+500$=1400mil.$